On May 21, 2024, Processa Pharmaceuticals, Inc. announced the entry into a sales agreement with A.G.P./Alliance Global Partners to potentially issue and sell shares of its common stock in an 'at the market offering' with a total offering price of up to $2.4 million. The proceeds from the sale are intended for research and development of the company's drug candidates, particularly in oncology, as well as for working capital and general corporate purposes. The shares will be sold at prevailing market prices, and the sales agent will receive up to 3% of the gross proceeds from the sales. The agreement allows for sales to be made directly to the sales agent as well. There is no obligation for Processa Pharmaceuticals...Show More

On May 21, 2024, Processa Pharmaceuticals, Inc. announced the entry into a sales agreement with A.G.P./Alliance Global Partners to potentially issue and sell shares of its common stock in an 'at the market offering' with a total offering price of up to $2.4 million. The proceeds from the sale are intended for research and development of the company's drug candidates, particularly in oncology, as well as for working capital and general corporate purposes. The shares will be sold at prevailing market prices, and the sales agent will receive up to 3% of the gross proceeds from the sales. The agreement allows for sales to be made directly to the sales agent as well. There is no obligation for Processa Pharmaceuticals to sell any shares, and there is no guarantee regarding the amount of shares that may be sold or the timing of any sales. The sales agreement will terminate when all shares are sold or as stipulated in the agreement. The offering is contingent upon the effectiveness of the company's registration statement on Form S-3 and the related prospectus supplement, which have been filed with the SEC but are not yet effective.